BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis Clinical Trial

Official title:

Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center, Four Week Trial of BIRB 796 BS 5, 10, 20 and 30 mg Oral Tablets Versus Placebo Administered BID in Patients With Moderate to Severe Plaque-type Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02209753
• Other study ID #: 1175.10
• Status: Completed
• Phase: Phase 2
• First received: August 5, 2014
• Last updated: August 5, 2014
• Start date: June 2001

Study information

• Verified date: August 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Public Health Agency of Canada
• Study type: Interventional

Clinical Trial Summary

The clinical objective of this study was to determine the effect of BIRB 796 BS on pharmacodynamic markers of psoriasis as a measure of efficacy, to determine the population pharmacokinetics of BIRB 796 BS and to determine the safety of BIRB 796 BS over 4 weeks of treatment in patients with moderate to severe plaque-type psoriasis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 182
• Est. primary completion date: September 2002
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with stable moderate to severe plaque-type psoriasis involving =5% body surface area

• History of plaque psoriasis for a minimum of 6 months prior to screening

• Age 18 - 75

• Males or females, females must be of non-childbearing potential (6 months post-menopausal, surgically sterilized) or using an approved form of birth control (oral contraceptives, Norplant®, Depo-Provera®, intrauterine device (IUD), double-barrier) and have a negative serum pregnancy test upon screening (Visit 1) and a negative urine test prior to randomization (Visit 2) into the trial

• Give informed consent and sign an approved consent form prior to any study procedures, including washout of prohibited medications

Exclusion Criteria:

• Primary guttate, erythrodermic, or pustular psoriasis

• Psoriasis which has failed to improve significantly with systemic treatments such as cyclosporine or methotrexate. Patients resistant to one, but have had a documented response to another may be included with approval of the medical monitor. Treatment failure will not include failure to improve if a full course of treatment was unable to be completed due to adverse events, intolerance of the treatment or administrative reasons

• Patients who have experienced treatment failure with a TNF-blocking agent. Treatment failure is defined as not achieving at least a 40% reduction in PASI score or having the TNF-blocking agent discontinued due to lack of efficacy

• Patients unable to wash out of all current psoriasis treatments (systemic, topical and phototherapy) except emollients and shampoos prior to beginning trial medication

• Patients taking the following medications known to elevate liver enzymes who have not been taking these medications at a stable dose for at least 1 month (3 months for diclofenac) without changes to liver functions tests (LFTs) prior to randomization (Visit 2): estrogens, oral contraceptives, selective serotonin reuptake inhibitors (SSRIs), nonsteroidal anti-inflammatory drugs (NSAIDs), acetominophen =3 g/day, aspirin, vitamin supplements (at recommended daily allowance doses). Patients taking doses of acetaminophen greater than three grams per day are excluded. Any other medication known to elevate hepatic enzymes not listed above is excluded

• Patients using any of the medications listed in the protocol, without the appropriate washout period

• Patients with clinically significant abnormal baseline hematology, blood chemistry or urinalysis if the abnormality defines a disease listed as an exclusion criterion. All patients with a serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase , alkaline phosphatase greater than 1.5 x upper limit of normal (ULN) or total bilirubin greater than 1.0 x ULN will be excluded regardless of the clinical condition. Patients with serum creatinine, white blood cell (WBC) count, amylase, lipase, prothrombin time (PT), partial thromboplastin time (PTT), D-dimer, fibrin degradation product (FDP) greater than 1.5 x ULN, or blood smear poikilocytes or schistocytes greater than 1.0 x ULN will also be excluded. Patients with hemoglobinuria or proteinuria greater than 1+ will be excluded. Hemoglobinuria must be confirmed as hematuria with finding of red blood cell (RBC) on microscopic examination. Hematuria in a menstruating female will not require exclusion but must be repeated after menses has cleared prior to entry. Repeat laboratory testing is allowed once at screening prior to excluding the patient, to avoid excluding patients with transient or erroneous abnormal laboratory values

• Any clinically significant psychiatric illness which may interfere with the patient's participation in the trial or ability to interpret the trial results

• History of cardiovascular, renal, neurologic, liver, immunologic or endocrine dysfunction if they are clinically significant. A clinically significant disease is defined as one which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study

• Patients with any history of heart failure, patients with a recent history (i.e., 1 year or less) of myocardial infarction or patients with any arrhythmia requiring drug therapy

• Any ECG value outside of the reference range of clinical relevance including, but not limited to, QTcB >480 ms, PR interval >240 ms, QRS interval >110 ms

• History of malignancy in the past 5 years except treated cutaneous squamous cell or basal cell carcinoma

• Any active immunodeficiency or active infection, or any serious infection (requiring hospitalization or IV/intramuscular antibiotics) in the past 3 months prior to screening. Patients testing positive to human immunodeficiency virus (HIV), hepatitis B or hepatitis C will be excluded

• History of prior tuberculosis infection or active tuberculosis, patients must have a negative skin test or chest x-ray within the past 6 months prior to screening (Visit 1)

• History of drug or alcohol abuse within the past 2 years, active drug or alcohol abuse, or patients who consume more than three alcoholic drinks per day

• Patients who have taken an investigational drug within one month (30 days) or six half lives (whichever is greater) prior to screening (Visit 1). Patients who have been treated with any investigational antibody or other biological agent within the past 3 months are excluded

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• BIRB 796 BS, low dose

• BIRB 796 BS, medium dose 1

• BIRB 796 BS, medium dose 2

• BIRB 796 BS, high dose

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline for the total Psoriasis Area and Severity Index (PASI) score		after 4 weeks of treatment	No
Primary	Percent change from baseline for pathological thickness		after 4 weeks of treatment	No
Primary	Percentage of K16 negative assessments		at week 4	No
Primary	Number of patients with adverse events		up to 120 days	No
Primary	Number of patients with clinically significant effects on laboratory values		up to 36 days	No
Primary	Number of patients with abnormal findings in electrocardiogram		up to day 29	No
Primary	Number of patients with clinically significant changes in vital signs		up to day 36	No
Secondary	Absolute change from baseline in the number of epidermal T cells		after 4 weeks of treatment	No
Secondary	Absolute change from baseline in the number of dermal T cells		after 4 weeks of treatment	No
Secondary	Relative (%) change from baseline in the number of dermal T cells		after 4 weeks of treatment	No
Secondary	Relative (%) change from baseline in the number of epidermal T cells		after 4 weeks of treatment	No
Secondary	PASI 50 responder	reduction of total PASI score by 50% or more	after 4 weeks of treatment	No
Secondary	Assessment of target lesions on a 5-point numeric scale		day 1 and 29	No
Secondary	Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) gene expression for cytokines		days 1, 8 and 29	No
Secondary	Reduction of serum immunological markers of disease activity		day 1 and 29	No
Secondary	Change in score of total body lesion		day 1 and 29	No
Secondary	Reduction of inducible nitric oxide synthase (iNOS)		day 1 and 29	No
Secondary	PASI 75 responder	reduction of total PASI by 75%	after 4 weeks of treatment	No
Secondary	Histopathological global assessment on a 4-point scale		after 4 weeks of treatment	No
Secondary	Keratin K16 improvement score		after 4 weeks of treatment	No
Secondary	20% reduction responder variable for pathological thickness		after 4 weeks of treatment	No
Secondary	20% reduction responder variable for iNOS		after 4 weeks of treatment	No
Secondary	Reduction of K16 mRNA		day 1 and 29	No
Secondary	Reduction of COX-2 mRNA		day 1 and 29	No
Secondary	20% reduction responder variable for K16		after 4 weeks of treatment	No
Secondary	20% reduction responder variable for interleukin 8 mRNA		after 4 weeks of treatment	No

External Links

•   Link